34582 Federal Register / Vol. 83, No. 140 / Friday, July 20, 2018 / Notices 

the services to be performed, outside the 

United States has an estimated value 

that exceeds $500,000. These 

protections include the following: (a) 

The contractor is required to implement 

and maintain a compliance plan during 

the performance of the contract that 

includes an awareness program, a 

process for employees to report activity 

inconsistent with the zero-tolerance 

policy, a recruitment and wage plan, a 

housing plan, and procedures to prevent 

subcontractors from engaging in 

trafficking in persons; and (b) The 

contractor is required to submit a 

certification to the contracting officer 

prior to receiving an award, and 

annually thereafter, asserting that it has 

the required compliance plan in place 

and that there have been no abuses, or 

that appropriate actions have been taken 

if abuses have been found. The 

compliance plan must be provided to 

the contracting officer upon request, and 

relevant portions of it must be posted at 

the workplace and on the contractor’s 

website. Additionally, contractors are 

required to flow these requirements 

down to any subcontracts where the 

estimated value of the supplies acquired 

or the services required to be performed 

outside the United States exceeds 

$500,000. 

B. Annual Reporting Burden 

Title, Associated Form, and OMB 

Number: Ending Trafficking in Persons, 

FAR 22.1705 and FAR 52.222–50 and 

52.222–56; OMB Control Number 9000– 

0188. 

Adjustment: This information 

collection is revised to include 

appropriate burden hours for reporting 

that was initially published in FAR Case 

2013–001 (78 FR 59317 and 80 FR 4967) 

for FAR clause 52.222–50, Combating 

Trafficking in Persons, and provision 

52.222–56, Certification Regarding 

Trafficing in Persons Compliance Plan. 

The full burden associated with this 

FAR Case was inadvertently omitted in 

the Paperwork Reduction Act notice 

published on August 20, 2014 (78 FR 

59317). The following represents 

current burdens associated with the 

FAR clause and provision that were 

published in the proposed and final 

rules. 

Affected Public: Businesses and other 

for-profit entities. 

Respondent’s Obligation: Required to 

obtain or retain benefits. 

Type of Request: Revision of a 

currently approved collection. 

Reporting Frequency: On occasion. 

Respondents: 5,909. 

Responses per Respondent: 3. 

Annual Responses: 17,727. 

Hours per Response: 12. 

Total Burden Hours: 212,724. 

C. Public Comment 

A notice was published in the Federal 

Register at 83 FR 12950, on March 26, 

2018. No comments were received. 

Obtaining Copies of Proposals: 

Requesters may obtain a copy of the 

information collection documents from 

the General Services Administration, 

Regulatory Secretariat Division (MVCB), 

1800 F Street NW, Washington, DC 

20405, telephone 202–501–4755. Please 

cite OMB Control No. 9000–0188, 

Combating Trafficking in Persons, in all 

correspondence. 

Dated: July 17, 2018. 

William Clark, 

Director, Office of Governmentwide 

Acquisition Policy, Office of Acquisition 

Policy, Office of Governmentwide Policy. 

[FR Doc. 2018–15523 Filed 7–19–18; 8:45 am] 

BILLING CODE 6820–EP–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket No. CDC–2017–0059] 

Notice of Availability of Final 

Environmental Impact Statement; Site 

Acquisition and Campus Consolidation 

for the Centers for Disease Control and 

Prevention/National Institute for 

Occupational Safety and Health (CDC/ 

NIOSH), Cincinnati, Ohio 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of availability. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC) within 

the Department of Health and Human 

Services (HHS), in cooperation with the 

U.S. General Services Administration 

(GSA), announces the availability of the 

Final Environmental Impact Statement 

(EIS) for the proposed acquisition of a 

site in Cincinnati, Ohio, and the 

development of this site into a new, 

consolidated CDC/National Institute for 

Occupational Safety and Health 

(NIOSH) campus (Proposed Action). 

The site being considered for 

acquisition and development is 

bounded by Martin Luther King Drive 

East to the south, Harvey Avenue to the 

west, Ridgeway Avenue to the north, 

and Reading Road to the east. 

The Final EIS and this notice are 

published pursuant to the requirements 

of the National Environmental Policy 

Act of 1969 (NEPA) as implemented by 

the Council on Environmental Quality 

(CEQ) Regulations. 

DATES: CDC will issue a final decision 

on the proposed action after August 20, 

2018. 

ADDRESSES: Copies of the Final EIS can 

be obtained at: 

• Federal eRulemaking Portal: http:// 

www.regulations.gov (reference Docket 

No. CDC–2017–0059). 

• By Written Request (Electronic 

Copies Only) to: cdc-cincinnati-eis@

cdc.gov or Harry Marsh, Architect, 

Office of Safety, Security and Asset 

Management (OSSAM), Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS–K80, Atlanta, 

Georgia 30329–4027. 

All U.S. Mail communications must 

include the agency name and Docket 

Number. 

FOR FURTHER INFORMATION CONTACT: 

Harry Marsh, Architect, Office of Safety, 

Security and Asset Management 

(OSSAM), Centers for Disease Control 

and Prevention, 1600 Clifton Road NE, 

MS–K80, Atlanta, Georgia 30329–4027, 

phone: (770) 488–8170, or email: cdccincinnati-eis@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Background: CDC is dedicated to 

protecting health and promoting quality 

of life through the prevention and 

control of disease, injury, and disability. 

NIOSH, one of CDC’s Centers, Institutes, 

and Offices, was established by the 

Occupational Safety and Health Act of 

1970. NIOSH plans, directs, and 

coordinates a national program to 

develop and establish recommended 

occupational safety and health 

standards; conduct research and 

training; provide technical assistance; 

and perform related activities to assure 

safe and healthful working conditions 

for every working person in the United 

States. 

Currently, three NIOSH research 

facilities—the Robert A. Taft Campus, 

Taft North Campus, and the Alice 

Hamilton Laboratory Campus—are 

located in Cincinnati, Ohio. These 

facilities no longer meet the research 

needs required to support occupational 

safety and health in the modern 

workplace. The facilities’ deficiencies 

adversely affect NIOSH’s ability to 

conduct occupational safety and health 

research in Cincinnati. It is not possible 

to renovate the facilities located on the 

three campuses to meet current 

standards and requirements. 

Additionally, the current distribution of 

NIOSH activities across separate 

campuses in Cincinnati results in 

inefficiencies in scientific collaboration 

and the duplication of operational 

support activities. Therefore, CDC is 


daltland on DSKBBV9HB2PROD with NOTICES
Federal Register / Vol. 83, No. 140 / Friday, July 20, 2018 / Notices 34583 

proposing to relocate and consolidate its 

Cincinnati-based functions and 

personnel (approximately 550 

employees) currently housed at the 

three existing campuses to a new, 

consolidated campus in Cincinnati. 

Potential locations for the proposed 

new campus were identified through a 

comprehensive site selection process 

conducted by GSA on behalf of CDC. In 

June 2016, GSA issued a Request for 

Expressions of Interest (REOI) seeking 

potential sites capable of 

accommodating the proposed new 

campus. In response to the REOI, GSA 

received seven expressions of interest. 

Following an assessment of each site, 

GSA found that only one site qualified 

for further consideration (The Site). The 

Site encompasses all land between 

Martin Luther King Drive East to the 

south, Harvey Avenue to the west, 

Ridgeway Avenue to the north, and 

Reading Road to the east in Cincinnati, 

Ohio. 

Under NEPA, as implemented by CEQ 

Regulations (40 CFR parts 1500–1508), 

Federal agencies are required to 

evaluate the environmental effects of 

their proposed actions and a range of 

reasonable alternatives to the proposed 

action before making a decision. On 

February 9, 2018, in accordance with 

NEPA, CDC published a Notice of 

Availability announcing that a Draft EIS 

for the proposed acquisition and 

campus consolidation had been 

prepared (83 FR 5774). The Draft EIS 

evaluated the potential impacts of two 

alternatives: The Proposed Action 

Alternative (acquisition of the Site and 

construction of a new, consolidated 

CDC/NIOSH campus) and the No Action 

Alternative (continued use of the 

existing campuses for the foreseeable 

future). Impacts on the following 

resources were considered: Land use, 

zoning, and plans; community facilities; 

socioeconomics and environmental 

justice; utilities and infrastructure; 

visual quality; cultural resources; 

transportation; geology, topography, and 

soils; air quality; noise; and hazardous 

substances. 

Publication of the Draft EIS notice 

initiated a 45-day review period, which 

ended on March 26, 2018. During this 

period, CDC received comments from 

government agencies, a Native 

American tribe, and the public. These 

comments pertained to the proposed 

action in general; the accessibility of the 

proposed campus site for bicyclists; 

historic buildings; traffic and air quality 

impacts; sustainability; and the 

potential displacement of neighborhood 

residents. 

All comments were considered when 

preparing the Final EIS and responses to 

the comments are provided in the Final 

EIS. No comment required substantive 

revisions to the analyses presented in 

the Draft EIS or to the alternatives 

considered. The Final EIS identifies the 

Proposed Action Alternative as CDC’s 

Preferred Alternative. 

CDC will make a decision on whether 

to proceed with the proposed action 

after August 20, 2018. At that time, CDC 

will issue a Record of Decision 

documenting and explaining its 

decision based on the Final EIS. 

Questions on the Final EIS and the 

proposed action may be directed to: 

Harry Marsh, Architect, Office of Safety, 

Security and Asset Management 

(OSSAM), Centers for Disease Control 

and Prevention, 1600 Clifton Road NE, 

MS–K80, Atlanta, Georgia 30329–4027, 

phone: (770) 488–8170, or email: cdccincinnati-eis@cdc.gov. 

Dated: July 16, 2018. 

Sandra Cashman, 

Executive Secretary, Centers for Disease 

Control and Prevention. 

[FR Doc. 2018–15410 Filed 7–19–18; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30 Day–18–0307] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

In accordance with the Paperwork 

Reduction Act of 1995, the Centers for 

Disease Control and Prevention (CDC) 

has submitted the information 

collection request Gonococcal Isolate 

Surveillance Project to the Office of 

Management and Budget (OMB) for 

review and approval. CDC previously 

published a ‘‘Proposed Data Collection 

Submitted for Public Comment and 

Recommendations’’ notice on February 

5, 2018 to obtain comments from the 

public and affected agencies. The CDC 

received 2 non-substantive comments 

related to the previous notice. This 

notice serves to allow an additional 30 

days for public and affected agency 

comments. 

CDC will accept all comments for this 

proposed information collection project. 

The Office of Management and Budget 

is particularly interested in comments 

that: 

(a) Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

(b) Evaluate the accuracy of the 

agencies estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

(c) Enhance the quality, utility, and 

clarity of the information to be 

collected; 

(d) Minimize the burden of the 

collection of information on those who 

are to respond, including, through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses; and 

(e) Assess information collection 

costs. 

To request additional information on 

the proposed project or to obtain a copy 

of the information collection plan and 

instruments, call (404) 639–7570 or 

send an email to omb@cdc.gov. Direct 

written comments and/or suggestions 

regarding the items contained in this 

notice to the Attention: CDC Desk 

Officer, Office of Management and 

Budget, 725 17th Street NW, 

Washington, DC 20503 or by fax to (202) 

395–5806. Provide written comments 

within 30 days of notice publication. 

Proposed Project 

Gonococcal Isolate Surveillance 

Project (0920–0307) (Exp. Date 02/28/ 

2019)—Revision—National Center for 

HIV, Viral Hepatitis, STD, and TB 

Prevention (NCHHSTP), Centers for 

Disease Control and Prevention (CDC). 

Background and Brief Description 

The Gonococcal Isolate Surveillance 

Project (GISP) was created in 1986 to 

monitor trends in antimicrobial 

susceptibilities of Neisseria gonorrhoeae 

strains in the United States. GISP 

continues to be a collaboration between 

different branches of the CDC Division 

of STD Prevention within the National 

Center for HIV, Viral Hepatitis, STD, 

and TB Prevention (NCHHSTP), 

selected regional laboratories and 

selected state/local public health 

departments and their associated STD 

specialty care clinics in the U.S. 

National organizations, local 

jurisdictions and individuals use data 

collected in GISP to understand and 

prevent antibiotic resistance in N. 

gonorrhoeae. Data from GISP are used to 

establish a scientific basis for the 

selection of gonococcal therapies and to 

allow pro-active changes to treatment 

guidelines before widespread resistance 

and failures of treatment occur. To 

increase capacity to detect and monitor 

resistant gonorrhea and to improve the 

specificity of GISP, this revision is being 


daltland on DSKBBV9HB2PROD with NOTICES